Today, just over two weeks from the launch of the Open Pharma position statement on open access, we reflect on how the statement came about, the benefits it offers to different types of stakeholders and the success it has had so far.
Last week was International Open Access Week covering the topic ‘Open for whom? Equity in open knowledge’. Open Pharma kicked off this year’s Open Access Week with the launch of its position statement on open access at a MedComms Networking event in Oxford on 21 October 2019. The statement calls for publishers to allow authors … Continue reading Find out what Open Pharma achieved during Open Access Week 2019
The Association of the British Pharmaceutical Industry (ABPI) has said that it wants to take transparency to the next level, and has committed to making clinical research more accessible and understandable across the pharmaceutical industry.
Evidence is essential for identifying treatment priorities and developing polices, said Claire Allen of Evidence Aid, at Evidence-Based Medicine Live (EBMLive), which took place on 15–17 July in Oxford, UK.
When it comes to driving change in academic publishing practices, much of the focus is on making research outputs freely available to all those who wish to access them. However, open access publishing is just the tip of the iceberg.
On 15 May 2019, the Center for Biomedical Research Transparency (CBMRT) brought the stakeholders in academic publishing together to share their varying perspectives on research transparency and accessibility at the European Biomedical Transparency Summit (BMTS), in Paris.
Featuring the release of the latest European University Association Open Access Survey results, the ordering of a predatory publisher to pay millions of dollars for deception, the adoption of Creative Commons licences by the European Commission and the launch of PeerJ-SciHub.
New Open Pharma resource: open access educational materials
In January 2019, Open Pharma core members and supporters attended a roundtable meeting, hosted by The BMJ at its Head Office at BMA House in London.
Last week’s ISMPP-U webinar ‘Open Access and Medical Publishing’, developed by the Medical Publishing Insights & Practices (MPIP) initiative and Open Pharma and moderated by LaVerne Mooney (Pfizer) and Chris Winchester (Oxford PharmaGenesis), aimed to define the key elements of open access policies, to provide insight into the changing publishing environment and to understand the perspectives of non-commercial and commercial stakeholders on open access publishing.